F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer
In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.nytimes.com — the content belongs to The New York Times.